期刊
ONCOLOGY REPORTS
卷 36, 期 1, 页码 559-566出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2016.4809
关键词
prostate cancer; Skp2; paclitaxel resistance; p27; E-cadherin
类别
资金
- National Natural Science Foundation of China [81130046, 81201669, 81171993, 81272415, 81560483]
- Natural Science Foundation of Guangxi [2013GXNSFAA019211, 2014GXNSFCA118009, 2013GXNSFEA053004, 2012GXNSFCB053004, 2013GXNSFBA019177, 1355004-5, 201201ZD004, GZPT13-35, 14122008-22, 11-031-05-K2, KY2015YB057, 14-045-12-K2]
- Guangxi Educational Committee [201106LX087, 201203YB034]
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients with hormone refractory prostate cancer are often treated with paclitaxel, but most of them eventually develop drug resistance. S-phase kinase associated protein 2 (Skp2) is a component of the SCF (Skp1-Cullin1-F-box) type of E3 ubiquitin ligase complexes. In the present study, we investigated the role of Skp2 in paclitaxel-resistant DU145-TxR or PC-3-TxR cells by Skp2 silencing or using Skp2 inhibitors. We first confirmed that Skp2 expression is upregulated in DU145-TxR or PC-3-TxR cells compared with their parental cells DU145 or PC-3, respectively. Knockdown of Skp2 or Skp2 inhibitor treatment in DU145-TxR or PC-3-TxR cells restored paclitaxel sensitivity. E-cadherin was decreased while Vimentin was increased in PC-3-TxR or DU145-TxR cells. In addition, p27 expression was inversely correlated with Skp2 expression in DU145-TxR or PC-3-TxR cells. Moreover, p27 was found to increase in both Skp2 silencing PC-3-TxR and DU145-TxR cells. These results suggest that Skp2 is associated with prostate cancer cell resistance to paclitaxel. Skp2 may be a potential therapeutic target for drug-resistant prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据